ACM
Aisling Capital Management Portfolio holdings
AUM
$479M
1-Year Est. Return
179.82%
This Fund
S&P 500
1 Year Est. Return
+179.82%
AUM
$479M
AUM Growth
+$22.5M
(+4.9%)
Holding
15
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
BridgeBio Pharma
BBIO
$12.9B
| $389M | 81.29% |
5,089,611
-1,000,000
|
|
||
2
Syndax Pharmaceuticals
SNDX
$1.92B
| $27.7M | 5.78% |
1,316,806
|
|
||
3
Monte Rosa Therapeutics
GLUE
$1.41B
| $23.1M | 4.82% |
1,472,331
|
|
||
|
BCAX
4
Bicara Therapeutics
BCAX
$964M
| $9.57M | 2% |
568,919
|
|
||
|
CMPS
5
Compass Pathways
CMPS
$797M
| $8.27M | 1.73% |
1,198,418
|
|
||
|
BBOT
6
BridgeBio Oncology
BBOT
$802M
| $7.07M | 1.48% |
564,625
|
|
||
7
CalciMedica
CALC
$7.31M
| $3.43M | 0.72% |
521,114
|
|
||
8
Scholar Rock
SRRK
$4.44B
| $3.39M | 0.71% |
77,031
|
|
||
9
Biomea Fusion
BMEA
$96.9M
| $2.54M | 0.53% |
2,048,757
|
|
||
10
UroGen Pharma
URGN
$890M
| $2.53M | 0.53% |
+108,000
|
|
||
11
Aclaris Therapeutics
ACRS
$311M
| $1.31M | 0.27% |
434,455
|
|
||
12
Marker Therapeutics
MRKR
$24.7M
| $485K | 0.1% |
325,370
|
|
||
|
OKUR
13
OnKure Therapeutics
OKUR
$36.7M
| $257K | 0.05% |
88,607
|
|
||
14
Nuvation Bio
NUVB
$2B
| – | – |
-2,960,659
|
|
||
|
VRNA
15
DELISTED
Verona Pharma
VRNA
| – | – |
-615,352
|
|